Corbus 提交 Reg FD 投资者演示 8-K：无新增临床或财务事实，CANYON-1 顶线数据为 9 月 14 日旧闻

----- crbp-20261015.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 15, 2026
CORBUS PHARMACEUTICALS HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37348
46-4348039
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
500 River Ridge Drive
Norwood
,
Massachusetts
02062
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code:
(
617
)
963-0100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
CRBP
The
Nasdaq
Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 Regulation FD Disclosure.
Corbus Pharmaceuticals Holdings, Inc. updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.l and incorporated herein by reference.
The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Investor Presentation
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Corbus Pharmaceuticals Holdings, Inc.
Date:
October 15, 2026
By:
/s/ Yuval Cohen
Name: Yuval Cohen
Title: Chief Executive Officer

----- crbp-ex99_1.htm -----
EX-99.1
2
crbp-ex99_1.htm
EX-99.1
Connecting Innovation
to Purpose Corporate Presentation October 15, 2026 Exhibit 99.1
This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. This presentation includes limited observations derived from separate clinical settings that are not, and should not be interpreted as, direct or indirect head‑to‑head comparisons of CRB‑701 or CRB‑913 with any other product. The observations described herein are subject to change as additional data become available, and future clinical trials of CRB‑701 or CRB‑913 may not reproduce, validate, or otherwise confirm these observations. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. Forward-Looking Statements
Peripherally restricted CB1 inverse agonist for obesity Competitive 5% placebo adjusted weight loss in Phase 1b at 12 weeks Favorable emerging safety and tolerability profile Phase 2 monotherapy study expected to start 1H 2027 > 1 billion people worldwide living with obesity OBESITY Differentiated portfolio in Oncology and Obesity Overview Oncology Obesity Pipeline of promising clinical assets targeting large commercial opportunities with significant unmet needs Nectin 4 ADC – OPSCC (lead), cervical cancer Promising Phase 1/2 2L data: 43% ORR at 3.6 mg/kg in OPSCC Registrational 2L OPSCC study (TEMPO-1) underway CRB-701 + pembrolizumab data in 1L OPSCC in Q1 2027 Potential BLA filing in 2L OPSCC in 2H 2028 Large TAM: ~14k 2L OPSCC eligible patients CRB-701 CRB-913
Focused and diversified pipeline Therapy Mechanism of Action Indication (rights) Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones CRB-701 Nectin-4 ADC positive
solid
tumors 2L OPSCC (US + Europe) First patient dosed in TEMPO-1 in Sept. 2026 1L OPSCC (US + Europe) Topline ORR data expected in Q1 2027 Cervical (US + Europe) Broad alignment with the FDA on registrational study CRB-913 Highly peripherally- restricted CB1 inverse agonist Obesity (Global) Phase 2 monotherapy study expected to commence 1H 2027 FDA Fast Track Designation granted HNSCC and Cervical $118M Cash, cash equivalents & investments as of June 30, 2026: approximately 18.7M common shares issued and outstanding (~22.4M fully diluted shares) PIPELINE FDA Fast Track Designation granted HNSCC and Cervical
Senior Management Team Yuval Cohen, PhD Chief Executive Officer, Director  Corbus co-founder and Chief Executive Officer since 2014. Previously the President
and co-founder of Celsus Therapeutics from 2005. Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience
in emerging biotech and medical device companies. Ian Hodgson, PhD Chief Operating Officer Dr. Hodgson joined Corbus in 2022. Previously he held senior leadership positions in biotech
and contract research organizations. Most recently served as V.P., Head of Clinical Services at TMC Pharma. Leo Nicacio, MD Chief Medical Officer Nishant Saxena, MBA Chief Business Officer Mr. Saxena joined Corbus in May 2026. Most recently he was CFO at Jeune Aesthetics, Inc. and previously was a healthcare investment banker at Evercore. Dr Nicacio joined Corbus in August 2026. Most recently he was the CMO at Protara and previously was VP of Clinical Development at Seagen.
Board of Directors Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience; currently CFO of ArriVent. (NASDAQ: AVBP) Yuval Cohen, PhD Chief Executive Officer, Director  Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005 Anne Altmeyer, PhD, MBA, MPH Director Greater than 25 years of experience advancing oncology R&D programs and leading impactful corporate development transactions; former CEO of TigaTx (acquired by Epsilogen Ltd.) Yong (Ben) Ben, MD, MBA Director 25 years of oncology R&D experience across industry and academia. CMO of BridgeBio Oncology Therapeutics and former CMO of BeiGene John K. Jenkins, MD Director Distinguished 25-year career serving at the U.S. FDA, including 15 years of senior leadership in CDER and OND Rachelle Jacques Chair of the Board More than 30-year professional career, experience in U.S.
and global biopharmaceutical commercial leadership, including multiple high-profile product launches in rare diseases; CEO of Vasque Bio and former CEO of Enzyvant Therapeutics (now Sumitomo Pharma) and Akari Therapeutics (NASDAQ: AKTX) Brent Pfeiffenberger, PharmD, MBA Director  President and CEO of Century Therapeutics (NASDAQ: IPSC). Former SVP Head of U.S Oncology at BMS
Anticipated corporate milestones Commence registrational study in 2L OPSCC CRB-701 + pembrolizumab in 1L OPSCC data Interim ORR readout in 2L OPSCC Potential BLA filing for 2L OPSCC Sept 2026 Q1 2027 1H 2028 2H 2028 CRB-701 Additional Phase 1b data at ObesityWeek® 2026 Initiate Phase 2 monotherapy study November 2026 1H 2027 CRB-913 Link to slides Link to slides
CRB-701 Next-Generation Nectin-4 ADC targeting oropharyngeal (OPSCC) and cervical cancers
CRB-701 DAY 1 1.25
mg/kg DAY 8 1.25
mg/kg DAY 15 1.25
mg/kg DAY 22 dose holiday DAY 28 DAY 1 CRB-701 DAY 8 dose holiday DAY 15 dose holiday DAY 22 CRB-701: Reimagining the next-generation Nectin-4 ADC Source(s): Modified image from Corbus data on file; Corbus data on file; PADCEV® FDA label MMAE = Monomethyl auristatin E; ADCC = antibody-dependent cellular cytotoxicity; CDC = complement dependent cytotoxicity Novel Nectin-4 Antibody ADCC + CDC functionality Glutamine Focused Side Chain Conjugation Payload: MMAE Microtubule Disruption Cathepsin-B Cleavage Site Precise & stable DAR of 2 2x internalization vs. PADCEV® Reduced free MMAE STRUCTURE
CRB-701-01 Study design (U.S. and Europe) cORR, confirmed objective response rate; DLT, dose-limiting toxicity; DoR, duration of response; MMAE, monomethyl auristatin E; PFS, progression-free survival; Q3W, every 3 weeks Dose Optimization (Project Optimus): HNSCC & cervical Dose escalation Dose escalation/
de-escalation decisions were made based on the occurrence of DLTs CRB-701
+ pembrolizumab
data expected
in Q1 2027 Dose levels in part B were defined by the pharmacologically active dose range identified in part A 1.8 mg/kg Q3W 21-day observation 2.7 mg/kg Q3W 21-day observation 3.6 mg/kg Q3W 21-day observation 4.5 mg/kg Q3W 21-day observation RANDOMIZATION 2.7 mg/kg Q3W 3.6 mg/kg Q3W 1:1 PHASE 1 DESIGN
Baseline Characteristic HNSCC Cervical Median age (range) 62 (24–78) 54 (32–78) Sex (M/F) 89.3% / 10.7% NA / 100% ECOG PS** 0, 1, 2 47%, 52%, 1% 44%, 56%, 0% Weight in kg mean (range) 75.2 (41.3–132.8) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–9) 3 (1–7) Enrolled Tumor Types Safety Population Efficacy Evaluable Population Non-evaluable* Study Population treated with monotherapy CRB-701
(All tumors, all doses, parts A+B of study) 317 NA NA HNSCC (2.7 mg/kg and 3.6 mg/kg) 75 71 4 Cervical (2.7 mg/kg and 3.6 mg/kg) 72 70 2 ASCO 2026: Key characteristics & tumor types Source(s): ASCO April 1, 2026 data cut **ECOG = Eastern Cooperative Oncology Group Performance Status; HNSCC = Head and Neck Squamous Cell Carcinoma *Patients enrolled but did not reach first scan BASELINE
TRAE n=317 (%) Grade 3 19.2% Grade 4 0.9% Grade 5 None PERIPHERAL NEUROPATHY (broad terms*) Grade 1 and 2 7.3% Grade >3 None SKIN (most common, excluding alopecia) Pruritus 14.2% Dry skin 13.2% Rash 5.7% Grade 3 - rash 0.3% Grade ≥4 None OCULAR Overall 66.2% Grade 3 12.6% Grade 4 0.3%** DISCONTINUATIONS Due to AE 2.8% Due to ocular AE 1.9% ASCO 2026: Study safety population TRAEs ≥20% (n=317) Source(s): ASCO April 1, 2026 data cut *Standardized MedDRA Category Search; ** Grade 4 resolved to Grade 1 following dose interruption; TRAEs = Treatment-Related Adverse Events  Fatigue PROPORTION OF PATIENTS (%) Dysgeusia Alopecia Keratitis SAFETY
Low rates of skin adverse events Eye toxicities manageable with prophylaxis and dose modification Potentially best-in-class for peripheral neuropathy ASCO 2026: Safety Summary (TRAEs, N=317) Source(s): ASCO April 1, 2026 data cut; *Standardized MedDRA Category Search; **general rash; TRAEs = Treatment-Related Adverse Events; 7.3% SAFETY (all Grade 1 or 2)* 15.5% Patients with
dose reductions 37.2% Patients with
dose interruptions 1.9% Few discontinuations
due to eye toxicities 1 in 4 Patients experienced
skin AEs (excluding alopecia) ONLY NO Cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) JUST A SINGLE Grade 3 event (1/317**) & NO Grade >4
CRB-701 in 2L+ Oropharyngeal Head and Neck Cancer (OPSCC)
Associated with higher
Nectin-4 expression2 HPV+ selectivity seen with PADCEV® in 1L HNSCC3 HPV+ tumors
(80–90%
of OPSCC)1 What is Oropharyngeal Squamous Cell Carcinoma (OPSCC)? Source(s): Image Corbus licensed ChatGPT account; 1. Ozdogan et al 2025; 2. Sander et al, 2022; 3. Swiecicki et al 2026. DEFINITION Oropharynx (includes tonsils, base of tongue, soft palate, and pharyngeal walls)
OPSCC is on the rise in the U.S. as prevalence of HPV+ in HNSCC
is increasing: 11%  57% over last 30 years Source(s): Data generated by Greenhill: (1) Portugal et al., 1997; (2) Dahlstrom et al., 2003; (3) Chaturvedi et al., 2008; (4) Cole et al., 2012; (5) Bauml et al., 2017; (6) Wu et al., 2021; (7) Sacco et al., 2021  (8) Chung et al., 2022; and (9) Corbus ASCO April 1, 2026 data cut OPSCC HPV+ RISING
↑ HPV+ Pathway ↓ HPV- Pathway Two Opposing Drivers ↑ HPV+ HNSCC (younger, non-smoking patients) ↓ HPV− HNSCC (older, heavy smoker/drinker patients) OPSCC growing in HNSCC: HPV+ incidence is growing while HPV- is decreasing Source(s): Data generated by Greenhill; (1) Chaturvedi, A. K. et al., 2011; (2) The ASCO Post. 2019, August 21; (3) Chen, A. M., 2024 Shift in sexual behavior (HPV is sexually transmitted) Tobacco control & public-health campaigns since the 1960s Oral HPV-16 transmission & persistent oropharyngeal infection Sharp decline in U.S. smoking and heavy alcohol use (1) (1) (1) (1) (2) (2) (3) U.S. Incidence per 100,000 OPSCC RISING
Summary of OPSCC U.S. Epidemiology and Treatment Eligibility Source(s): *LifeSci Consulting Qualitative Market Research ; **American Cancer Society Statistics 2026 for Oral Cavity and Oropharyngeal Cancer: 13,150 deaths and the Company estimates 7,000 attributable to OPSCC Total Prevalence: ∼114,000* Total Annual Incidence: ∼23,000* Annual Growth: ∼2% through 2040* Annual U.S. Deaths: ∼7,000** Keytruda monotherapy or Keytruda® + Platinum +/- 5FU or taxane Taxanes, cetuximab or 5FU monotherapy or in combination Incurable Setting: Recurrent locally Advanced or Metastatic Disease OPSCC
Enrolled Tumor Types HNSCC All-comers ( n=75 ) OPSCC Subset ( n=41 ) Other HNSCC anatomical subsets ( n=34 ) Median age (range) 62 (24–78) 62.0 (36–77) 62 (24–78) Sex (M/F) 89.3% / 10.7% 90.2% / 9.8% 88.2% / 11.8% ECOG PS 0, 1, 2 47%, 52%, 1% 58.5%, 41.5%, 0% 32.4%, 64.7%, 2.9% Weight in kg mean (range) 75.2 (41.3, 132.8) 79.0 (51.8, 132.8) 70.5 (41.3, 105.2) Prior therapies median (range) 3 (1–9) 3 (1–9) 2 (1–7) HPV Status
(Positive, Negative, Missing) 57.3%, 40%, 2.7% 85.4%, 14.6%, 0% 23.5%, 70.6%, 5.9% Disease status
(Locally Advanced or Metastatic) 16%, 84% 4.9%, 95.1% 29.4%, 70.6% ASCO 2026: Key characteristics in HNSCC and subsets Source(s): ASCO April 1, 2026 data cut ECOG = Eastern Cooperative Oncology Group Performance Status; HNSCC = Head and Neck Squamous Cell Carcinoma; OPSCC = Oropharyngeal Squamous Cell Carcinoma BASELINE
Nectin-4 H score>150 1 in 3 1 in 10 Nectin-4 H score>175 1 in 4 1 in 12 Nectin-4 H score>200 1 in 6 1 in 30 HNSCC ASCO 2026: OPSCC associated with HPV positivity in our study (as expected) and higher nectin-4 levels Source(s): ASCO April 1, 2026 data cut. BASELINE HPV+ HPV- Unknown
2.7 mg/kg 3.6 mg/kg cORR 20.0% (4/20) 42.9% (9/21) DCR 90.0% (18/20) 85.7% (18/21) 2.7 mg/kg 3.6 mg/kg cORR 7.1% (1/14) 0.0% (0/16) DCR 57.1% (8/14) 62.5% (10/16) ASCO 2026: CRB-701 confirmed responses favor OPSCC Source(s): ASCO April 1, 2026 data cut; Patients are summarized on the treatment and dose level assigned at enrollment/randomization. Best Overall Response is displayed at the end of each bar. HNSCC = Head & Neck Squamous Cell Carcinoma; OPSCC = Oropharyngeal anatomical subset of HNSCC; cORR = confirmed Objective Response Rate; DCR = Disease Control Rate OPSCC ( n=41 ) EFFICACY Non-OPSCC ( n=30 )
Subject Details WEEKS ON TREATMENT 3.6
mg/kg 2.7
mg/kg ASCO 2026: CRB-701 had longer durability in OPSCC Source(s): ASCO April 1,2026 data cut; HNSCC = Head & Neck Squamous Cell Carcinoma; OPSCC = Oropharyngeal Squamous Cell Carcinoma; DoR = Duration of Response; PFS = Progression-Free Survival HNSCC Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Treatment Ongoing Subject Details WEEKS ON TREATMENT 3.6
mg/kg 2.7
mg/kg HNSCC Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Treatment Ongoing OPSCC ( n=41 ) Non-OPSCC ( n=30 ) EFFICACY Endpoint (months) 2.7 mg/kg ( n=14 ) 3.6 mg/kg ( n=16 ) DoR 4.4 NA PFS 2.3 2.7 Endpoint (months) 2.7 mg/kg ( n=20 ) 3.6 mg/kg ( n=21 ) DoR 4.8 6.3 PFS 4.2 5.6
3.6 mg/kg Q3W OPSCC ( n=21 ) Non-OPSCC ( n=16 ) cORR 42.9% 0% DCR 85.7% 62.5% DoR (months) 6.3 NA PFS (months) 5.6 2.7 % responders HPV+ 89% (8 out of 9) NA ASCO 2026: Efficacy summary at 3.6 mg/kg Q3W OPSCC is
indication
of choice EFFICACY Source(s): ASCO April 2026 data cut; OPSCC = Oropharyngeal Squamous Cell Carcinoma;  cORR = confirmed Objective Response Rate; DCR = Disease Control Rate DoR = Duration of Response; PFS = Progression-Free Survival Supports 3.6 mg/kg dose for registrational studies
RP2D OPSCC population  Petosemtamab* (n=15)*** CRB-701** (n=21) Dosing regimen 1500 mg Q2W 3.6 mg/kg Q3W Efficacy (cORR) 13% (2/15) in OPSCC HPV+ only 50% (8/16) in OPSCC HPV+ only 43% (9/21) in OPSCC all types Median DoR (months) 6.2 in HNSCC 6.3 in OPSCC (ongoing) PFS (months) 4.9 in HNSCC 5.6 in OPSCC (ongoing) TRAEs Grade 3 & greater 59% in HNSCC 14.3% in OPSCC Contextualizing monotherapy CRB-701 and petosemtamab in 2L HPV+/OPSCC Source(s): * ESMO ASIA data Dec 2024. **ASCO April 1, 2026 data cut; *** Petosemtamab’s DOR PFS and TRAE was based total HNSCC study population(n=75) OPSCC = Oropharyngeal Squamous Cell Carcinoma; HNSCC = Head and Neck Squamous Cell Carcinoma; cORR = confirmed Objective Response Rate; DoR = Duration of Response; PFS = Progression-Free Survival PEERS
TEMPO-1 Registrational Study STUDY DESIGN ELIGIBLE POPULATION Recurrent OPSCC Prior Platinum & Anti–PD-(L)1 RANDOMIZED 3.6 mg/kg dose 1:1 CRB-701
Monotherapy
N≈125 INVESTIGATOR’S CHOICE Monotherapy
N≈125 ADAPTIVE FEATURE
Interim Analysis → Sample Size Re-Estimation
Seamless Phase 2 → Phase 3 Transition PRIMARY
(Accelerated Approval) ORR PRIMARY
(Full Approval) OS
Padcev® + Keytruda® cORR All 39% (16/41) HPV+ 82% (9/11) HPV- 23% (7/30) Notes: TRAEs ≥ Grade 3: 41% Peripheral neuropathy: 32% 1L OPSCC potential: the precedent of Padcev® + Keytruda®  in 1L Source(s): 1. Swiecicki et al 2026 2. Van Herpen ASCO 2025 3.Hanna et al 2026; cORR = confirmed Objective Response Rate Investigator-assessed cORR HPV+ cORR Peto + Keytruda®2 50% (4/8) Ficerafusp Alfa + Keytruda®3 27% (3/11) 1L POTENTIAL
Padcev® added to the 2026 NCCN treatment guidelines* for HNSCC * National Guidelines Version 2.2026 Head and Neck Cancer –Page 119 ** Swiecicki et al 2024 Swiecicki et al 2024** Padcev® 2L+ cORR All-comers 24% (11/46) Notes: Demographics: 65% U.S. & 35% Japan No breakdown by p16 TRAEs ≥ Grade 3: 35% Peripheral neuropathy: 24%
Cervical Cancer Acute unmet need in 2L in
poorly addressed market
Cervical Cancer: Commercial Opportunity for CRB-701 Source(s): 1. https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html , 2. Study reveals why cervical cancer screening rates are declining, which populations are most affected - UTHealth Houston School of Public Health , 3. HPV Vaccination | Cancer Trends Progress Report , 4. GlobalData Report-Cervical Cancer Global Drug and Market Analysis to 2030 Immigration of unvaccinated adult women Socio-economics and vaccine hesitancy Numbers
rising Girls ages 13–15 remain unvaccinated for HPV (2022 NIH data) Annual new cases in U.S. 4,000 annual deaths U.S. market for cervical cancer treatment 14,000 1 39% 3 $1.8B 4 2 CERVICAL CANCER
FULL APPROVAL Few options for 2L cervical cancer Source(s): Vergote et al 2024 1L 2L Tisotumab vedotin Single-Agent Chemo Carbo + Paclitaxel +/- Beva +/- Pembrolizumab ACCELERATED APPROVAL 2021 2024 CERVICAL CANCER
Efficacy**** ORR 17.8% PFS 4.2 months OS 11.5 months Adverse event profile**** Ocular (Black Box) 55% (all grades) Peripheral neuropathy 39% (all grades) Bleeding 51% (all grades) Rash 25% (all grades) USA numbers Value R/M patients receiving 2L treatment 38%* Annual price (WAC) $466,208** Annualized sales (global) $328mm*** Tivdak® demonstrates a commercial potential that could be further improved Source(s): *Leath et al. 2023, **MERCI Feb 2025, *** Tivdak sales for 9 months ended September 30, 2025 = $246mm-(Pfizer$115mm + Genmab $131mm), **** Per FDA Prescription Label CERVICAL CANCER
Enrolled Tumor Types Safety Population Efficacy Evaluable Population Cervical 72 70 Baseline Characteristic Cervical Median age (range) 54 (32, 78) Sex (M/F) NA/100% ECOG PS 0, 1, 2 44.4%, 55.6%, 0% Weight in kg mean (range) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–7) ASCO 2026: Key characteristics & tumor types Source(s): ASCO April 1, 2026 data cut ECOG = Eastern Cooperative Oncology Group Performance Status BASELINE
CRB-701 ASCO 2026: Waterfall plot (N=70) Source(s): ASCO April 2026 data cut; Patients are summarized on the treatment and dose level assigned at enrollment/randomization. Best Overall Response is displayed at the end of each bar. cCR = confirmed Complete response; cORR = confirmed Objective Response Rate; DCR = Disease Control Rate Best % Change from Baseline in Sum of Diameters (%) DOSE MG/KG 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) cCR 1 2 cORR 18.4% (7/38) 34.4% (11/32) DCR 55.3% (21/38) 75.0% (24/32) CERVICAL CANCER
Subject Details WEEKS ON TREATMENT 3.6
mg/kg 2.7
mg/kg CRB-701 ASCO 2026: Swimmer plots (N=70) Source(s): ASCO April 1, 2026 data cut; DoR = Duration of Response; PFS = Progression-Free Survival Months 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) DoR 6.8 8.0 PFS 2.8 4.3 CERVICAL Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Treatment Ongoing CERVICAL CANCER
CRB-701* ( n=32 ) Tivdak® ( n=253**) IC Chemo 2L+ ( n=249*** ) Mechanism Nectin-4 ADC with
MMAE payload (DAR 2) Tissue factor ADC with
MMAE payload (DAR 4) Anti-metabolite, cytoskeleton disruption, topoi inhibition etc. Target population 2L 2L 2L Dosing regimen 3.6 mg/kg Q3W 2 mg/kg Q3W various Efficacy (ORR)**  34.4% 17.8% 5.2% DoR months** 8.0 5.3 5.7 PFS months 4.3 4.2 2.9 OS months TBD 11.5 9.5 CRB-701 potential to differentiate from current standard of care in 2L Source(s): * ASCO April 1, 2026 data cut; ** Vergot et al 2024 ORR = Objective Response Rate; DoR = Duration of Response; PFS = Progression-Free Survival; OS = Overall survival CERVICAL CANCER
CRB-913 Daily oral small molecule targeting obesity
CANYON-1 summary Enrolled 254 patients across 15 U.S. clinical sites Trial representative of U.S. obesity population BMI average of 37 kg/m2 and 71% of participants female 5% placebo adjusted average weight loss at 12 weeks (60mg) Effect started early and deepened without plateauing All participants completing treatment with 60mg dose lost weight Emerging favorable safety and tolerability profile Favorable GI tolerability profile vs. published data on GLP-1s Psychiatric AEs broadly in line with published data on GLP-1s Data support
CRB-913’s
potential to deliver a novel non-incretin oral therapy for obesity
Cannabinoid Type-1 (CB1) is a well-characterized receptor (GPCR) in metabolism Note: G protein-coupled receptors (“GPCR”) are the largest and most common family of cell-surface receptors. PAPERS 10K in PubMed on CB1 and metabolism
CRB-913 higher peripheral exposure and lower brain exposure vs. prior CB1s Sources: Corbus murine data Corbus PK modeling based on Phase 1a data CRB-913 ~1/50th Brain:plasma ratio CRB-913 vs. Rimonabant1 ~1/15th Brain level CRB-913 vs. Monlunabant1 Rimonabant Otenabant Ibipinabant Taranabant Monlunabant ~30% Increase in peripheral levels
in humans vs. Monlunabant2
A 12-week Phase 1b randomized double-blinded placebo-controlled study in adults with obesity Study design All 15 sites located in US Randomization 1:1:1:1 n=254 Placebo QD 12-Week Treatment Phase ( CRB-913 or Placebo QD ) 20mg QD 20mg QD 40mg QD 20mg QD 40mg QD 60mg QD 4-week safety follow-up Weeks 2 4 12 16 Primary endpoint:
Safety and tolerability Secondary endpoints: Placebo adjusted weight loss from baseline and related outcomes N=65 N=61 N=62 N=66 Psychiatric safety assessments : GAD-7: Anxiety symptoms PHQ-9: Depressive symptoms C-SSRS: Suicidal ideation
Demographics Source: Corbus Pharmaceuticals (data on file) Baseline characteristics CRB-913 20mg ( n=65 ) CRB-913 40mg ( n=61 ) CRB-913 60mg ( n=62 ) Placebo ( n=66 ) Overall ( n=254 ) Female (%) 69.2 72.1 72.6 69.7 70.9 Caucasian (%) 67.7 65.6 75.8 54.5 65.7 Black or
African American (%) 30.8 31.1 17.7 36.4 29.1 Other (%) 1.5 3.2 6.4 9.0 5.2 Average age (years) 48.8 49.1 49.5 44.3 47.9 Average Weight (kg) 104.0 106.9 105.7 104.2 105.2 Average BMI kg/m2 37.6 38.0 37.2 37.1 37.5
Dose-dependent weight loss at 12 weeks with no plateauing Efficacy estimand. The LS means, and p-values are the Mixed Model for Repeated Measures (MMRM) with percent change from baseline as the dependent variable; sex, treatment group, visit and treatment group-by-visit interaction as categorical fixed effects, and the baseline weight as a covariate. An unstructured covariate matrix is used. Only participants with non-missing baseline and the respective visit are included. Weight loss 5.0% 2.8% 3.3%
Majority of participants lost weight on CRB-913 compared to placebo Note: Efficacy estimand. Analysis represents weight loss from baseline measured at day 85 for those participants who completed the study. Responder thresholds are cumulative; a participant who achieves a higher percentage of body-weight loss is also included in each lower-threshold category Source: Corbus Pharmaceuticals (data on file) Response rate
Comparable weight loss to oral GLP-1s published data at 12 weeks Note: Efficacy estimand. These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36 mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2 mg tablet commercial formulation. Competitor weight loss data at 12 weeks reflects published data from a 68-week study (oral semaglutide 25 mg, N Engl J Med 2025) and 36-week study (orforglipron, N Engl J Med 2023). Sources: Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link) Foundayo prescribing info (Link) Corbus Pharmaceuticals (data on file) Weight loss vs oral GLP-1s 4 Weeks 8 Weeks 12 Weeks CRB-913 placebo adjusted weight loss at 60mg dose, competitor weight loss data is a cross-trial comparison based on published studies 1 3 2 1 3 2 1 3 2
CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) All Treatment-Emergent AEs (TEAEs) 39 (60.0%) 45 (73.8%) 45 (72.6%) 28 (42.4%) Severe TEAEs 3 (4.6%) 2 (3.3%) 1 (1.6%) 0 Severe Psych TEAEs 0 0 0 0 Severe GI TEAEs 0 0 0 0 Serious TEAEs 2 (3.1%) 1 (1.6%) 1 (1.6%) 0 All Treatment-Related AEs (TRAEs) 27 (41.5%) 34 (55.7%) 33 (53.2%) 14 (21.2%) Severe TRAEs 0 1 (1.6%) (headache) 0 0 Serious TRAEs (SAEs) 0 0 0 0 Treatment Discontinuations due to AEs 2 (3.1%) 8 (13.1%) 8 (12.9%) 3 (4.5%) Treatment Discontinuations for any reason 10 (15.4%) 16 (26.2%) 16 (25.8%) 12 (18.2%) Favorable safety profile with low discontinuations and no serious TRAEs (assignment by cohort) Source: CANYON-1 data Safety and tolerability
Discontinuations due to AEs vs. oral GLP-1 class Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2mg tablet commercial formulation Sources: Corbus Pharmaceuticals (data on file). Represent treatment emergent GI AE’s Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link) Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link) AE dropout rate CRB-9131 (60mg) Orforglipron3 (36mg capsule – Cohort 1) Orforglipron3 (36mg capsule – Cohort 2) Oral semaglutide2 (25mg) # of patients
assigned drug 62 29 29 205 Duration
of study 12 weeks 36 weeks 36 weeks 64 weeks AE Treatment discontinuation 12.9% 10.3% 20.7% 6.9% Titration Schedule 2 titrations (every 2 weeks) 6 titrations (every week) 4 titrations (every 3 weeks) 3 titrations (every 4 weeks)
In-depth analysis of psychiatric safety profile
Suicidality, depression and anxiety were mostly mild,
all transient, and don’t appear dose-related Sources: CANYON-1 data, Ref 1: Lu W, et al. “Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database”. European Psychiatry 2005 (Link) Safety and tolerability: Psych CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) Suicidality 0 0 0 0 Depressive symptoms 0 0 1 (1.6%) (moderate) 0 Anxiety 2 (3.1%) 5 (8.2%) 3 (4.8%) 3 (4.5%) Treatment-emergent psychiatric AEs were mild or moderate with no serious or severe AEs Placebo cohort experienced psych AEs 50% of psych AEs occurred in first 28 days (similarly to GLP-1s1) All psych AE cases resolved with the majority continuing treatment
Suicidality, depression and anxiety were in line with published GLP-1 studies Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. Published safety data reflect adverse events reported over study durations longer than the 12-week CANYON-1 treatment period: 56-week study (liraglutide, Diabetes Obes Metab. 2017), 68-week study (semaglutide, JAMA Intern Med. 2024), and 72-week study (tirzepatide, Obesity 2026). Sources: O'Neil et al. “Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 (link) Wadden et al, et al. “Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med. 2024 (link) Wadden et al, “Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT ,” Obesity 2026 (link) Psych AE in context of GLP-1 CRB-913 (All doses) Liraglutide1 Semaglutide2 Tirzepatide3 Suicidality 0% 1% 0.3% 0.6% Depressive symptoms 0%–1.6% 3.0% 2.8%–4.6% 2.0% Anxiety 3.1%–8.2% 2.7% 3.3%–7.2% 1.9%
Irritability AE: Irritability occurred early, was always mild + transient  did not lead to any discontinuations Source: CANYON-1 data Irritability Placebo 20mg CRB-913 40mg CRB-913 60mg CRB-913 By assigned cohort 0 4 (6.2%) 5 (8.2%) 6 (9.7%) By dose at time of AE 0 7 5 3 All cases were mild and resolved  patients report no impact on daily function 12 out of 15 involved concomitant non-psych AEs (e.g., GI, migraines, ear infection, etc.) 15 out of 15 cases coincided with weight loss >50% of incident events occurred by week 4 (75% by week 6) None caused discontinuations
Onset of irritability was concentrated in the first 2 weeks Source: CANYON-1 data Irritability First onset of Irritability 7 1–2 2 3–4 2 5–6 1 7–8 9–10 0 11–12 1 13–14 0 15–16 20 mg 40 mg 60 mg Dose at time of event Study week >50% of events occurred by week 4 75% of events occurred by week 6 Treatment  period  2
Psych AE discontinuations: Analysis of psych AEs discontinuations based on dose vs. assigned cohort (factoring for titration) Psych discontinuations Placebo 20mg CRB-913 40mg CRB-913 60mg CRB-913 By assigned cohort 1 (1.5%) 1 (1.5%) 3 (4.9%) 5 (8.1%) By dose at time of AE 1 3 2 4 1 participant on placebo discontinued due to moderate anxiety No discontinuation due to irritability 5 out of 10 discontinuations on CRB-913 occurred by week 6, and none after week 10
CRB-913 (20/40/60mg) n = 188 Monlunabant1 (10/20/50mg) n = 180 Depression 0%–1.6% 3%–8% Anxiety 3.1%–8.2% 10%–27% Irritability 6.2%–9.7% 10%–17% Insomnia 0%–4.9% 7%–17% AE study discontinuation 1.5%–9.8% 13%–42% Severe psych AE None 2%–7% Unresolved psych AEs None 5%–17% CRB-913 demonstrates favorable psych safety to monlunabant in a cross-trial comparison (assignment by cohorts) Note: These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons with monlunabant which has been discontinued by Novo. Published safety data reflect adverse events reported over longer time periods than the 12-week CANYON-1 treatment period Source: Knop, F.K. et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet 2025 (Link) Psych AEs vs monlunabant
In-depth analysis
of GI safety profile
CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) Vomiting 3 (4.6%) 5 (8.2%) 1 (1.6%) 0 Nausea 10 (15.4%) 16 (26.2%) 14 (22.6%) 3 (4.5%) Constipation 3 (4.6%) 1 (1.6%) 3 (4.8%) 2 (3.0%) Diarrhea 14 (21.5%) 16 (26.2%) 14 (22.6%) 2 (3.0%) Treatment-emergent GI AEs of special interest were mild or moderate with no serious or severe AEs (by cohort assignments) Source: CANYON-1 data Safety and tolerability: GI AESIs No severe or serious GI TEAEs Treatment discontinuations due to GI AE: 2 on CRB-913 and 1 on placebo
Diarrhea occurs early, never serious or severe Source: CANYON-1 data. Numbers of patients with events by dose at time event initiation. Participants with events that spanned multiple dose levels are counted in the first dose that triggered the event and not subsequent dose levels. Diarrhea 70% of events occurred in first 2 weeks while on 20mg dose 85% cases mild; 15% moderate No cases of severe diarrhea
CRB-9131 (60mg cohort) Oral semaglutide2 (25mg) Orforglipron3 (36mg capsule - Cohort 1) Orforglipron3 (36mg capsule - Cohort 2) Orforglipron4 (FDA Label) Vomiting 1.6% 31% 28% 14% 24% Nausea 22.6% 47% 41% 48% 35% Constipation 4.8% 20% 28% 24% 24% Diarrhea 22.6% 18% 3% 14% 25% Potentially improved GI tolerability vs. commercial oral GLP-1s (by assigned cohort) Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2mg tablet commercial formulation. Published safety data reflect adverse events reported over longer time periods than the 12-week CANYON-1 treatment period Sources: Corbus Pharmaceuticals (data on file) . Data represents treatment emergent GI AEs Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link) Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link) Prescribing information for orforglipron (Link) GI AE in context of oral GLP-1 GI AEs were mild or moderate with no serious or severe AEs
Summary
and next steps
Data supports CRB-913 potential as new class of oral non-incretin obesity medicines Note: These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons Competitive monotherapy
& potential to evaluate in combination with GLP-1 Psych AE profile supports benefits of peripheral restriction of CB1 therapy Favorable GI profile 5% weight loss at 12 weeks with no evidence of plateauing (comparable to oral GLP-1)
CRB-913 moving forward  Phase 2 Anticipated next steps Present CANYON-1 dataset at ObesityWeek as a late breaker Engage with FDA regarding clinical development plan Initiate Phase 2 monotherapy study in 1H 2027 ("CANYON-2") Evaluate potential combination therapies
Addressable market opportunity for CRB-913 is significant Sources: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet 2024 (Link) World Health Organization. Obesity and overweight. WHO Fact Sheet 2025 (Link) American Medical Association, (Link) Cartwright et al 2025; **AP Nov 2024 Monotherapy Target Markets Combination therapy Lifelong maintenance >1 billion
people worldwide with obesity1 ~ 3 billion people worldwide overweight2 ~23%
intolerant
to incretins4 64% of
GLP-1 users discontinue
at 1 Yr4 ~20% non-responders4 to incretins >200 associated
co-morbidities3
Thank you!